Re: e-ESC online discussion of Her2+ MBC management
This turned out for me to be a very informative summation of the data which is currently used to plan treatment strategies for Her2+ MBC, at least in the clinical trial setting. The discussions about Petuzamab + Herceptin and TDM-1 were the most encouraging to me. I will admit that most of that information has been discussed on our forum in recent past, but it is always good to get it summarized by practicing oncologists. I would recommend that anyone not able to tune in to the live webcast today might check back with the ESO website in the next few days to see when the video of the presentation is up for viewing. It will be an hour well spent, IMHO.---bird
__________________
Male Breast Cancer, DX 5/15/09, IDC, STAGE 1, 1.7 cm, HER2+++, ER+(95%)/PR+(75%), Ki67 40%, grade 3, 0/5 nodes, TX: mastectomy, TCH finished 7/19/10, radiation 6 wks., Tamoxifen on going, bisphosphonate 24 mos.
|